Department of Cardiology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Department of Perfusion, Ghent University Hospital, Ghent University, Ghent, Belgium.
Perfusion. 2023 Nov;38(8):1577-1583. doi: 10.1177/02676591221119319. Epub 2022 Aug 15.
Coronavirus disease 2019 (COVID-19) leads to thoracic complications requiring surgery. This is challenging, particularly in patients supported with venovenous extracorporeal membrane oxygenation (VV-ECMO) due to the need for continuous therapeutic anticoagulation. We aim to share our experience regarding the safety and perioperative management of video-assisted thoracic surgery for this specific population.
Retrospective, single-center study between November 2020 and January 2022 at the ICU department of a 1.061-bed tertiary care and VV-ECMO referral center during the COVID-19 pandemic.
48 COVID-19 patients were supported with VV-ECMO. A total of 14 video-assisted thoracic surgery (VATS) procedures were performed in seven patients. Indications were mostly hemothorax (85.7%). In eight procedures heparin was stopped at least 1 h before incision. A total of 10 circuit changes due to clot formation or oxygen transfer failure were required in six patients (85.7%). One circuit replacement seemed related to the preceding VATS procedure, although polytransfusion might be a contributing factor. None of the mechanical complications was fatal. Four VATS-patients (57.1%) died, of which two (50%) immediately perioperatively due to uncontrollable bleeding. All three survivors were treated with additional transarterial embolization.
(1) Thoracic complications in COVID-19 patients on VV-ECMO are common. (2) Indication for VATS is mostly hemothorax (3) Perioperative mortality is high, mostly due to uncontrollable bleeding. (4) Preoperative withdrawal of anticoagulation is not directly related to a higher rate of ECMO circuit-related complications, but a prolonged duration of VV-ECMO support and polytransfusion might be. (5) Additional transarterial embolization to control postoperative bleeding may further improve outcomes.
2019 年冠状病毒病(COVID-19)可导致需要手术的胸部并发症。这是具有挑战性的,特别是对于那些因持续的治疗性抗凝而需要支持静脉-静脉体外膜肺氧合(VV-ECMO)的患者。我们旨在分享我们在 COVID-19 大流行期间在 ICU 部门对这一特定人群进行电视辅助胸腔手术的安全性和围手术期管理经验。
2020 年 11 月至 2022 年 1 月期间,在一家拥有 1061 张病床的三级护理和 VV-ECMO 转诊中心的 ICU 部门进行了一项回顾性、单中心研究。
48 名 COVID-19 患者接受了 VV-ECMO 支持。在七名患者中总共进行了 14 次电视辅助胸腔手术(VATS)。适应症主要为血胸(85.7%)。在八次手术中,肝素在切口前至少 1 小时停止。六名患者(85.7%)因凝血块形成或氧传递失败需要更换总共 10 个回路。尽管多输血可能是一个促成因素,但似乎只有一个回路更换与之前的 VATS 手术有关。没有一个机械并发症是致命的。四名 VATS 患者(57.1%)死亡,其中两名(50%)立即在围手术期因无法控制的出血而死亡。所有三名幸存者均接受了额外的经动脉栓塞治疗。
(1)VV-ECMO 上的 COVID-19 患者的胸部并发症很常见。(2)VATS 的适应症主要是血胸。(3)围手术期死亡率很高,主要是由于无法控制的出血。(4)术前停止抗凝与 ECMO 回路相关并发症的发生率没有直接关系,但长时间的 VV-ECMO 支持和多输血可能是相关的。(5)额外的经动脉栓塞治疗以控制术后出血可能会进一步改善结果。